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Abstract Peripheral dedifferentiated chondrosarcoma
(DCS) is an exceedingly rare aggressive surface bone neo-
plasm in which a high-grade sarcoma arises within an
osteochondroma. Four such examples were identified in
our files, representing 11.1% of all DCS treated at our
hospital in the years 1995–2010, and were the object of
the present study. The patients were two men and two
women ranging in age between 30 and 64 years, with
tumors located in the pelvis (n 0 2), in the scapula (n 0 1),
and the tibia (n 0 1). Radiologically, there was evidence of a
preexisting osteochondroma associated with aggressive
osteolytic areas at the base and periphery of the exostosis,
extending to the bone segment of origin and to the soft
tissues. Immunohistochemical analysis of cell cycle regula-
tors showed consistent loss in the expression of p16 and
overexpression of cyclin D1, and to a lesser extent of RB
and p53, in the anaplastic compartments of peripheral DCS
in comparison with the well-differentiated cartilaginous
components, while no significant expression of MDM2
was observed in any of the cases studied. Moreover,
PDGFR! was absent in both tumor components, and
PDGF-R" was strongly and diffusely positive in all the
cases. Finally, no mutations were identified in exons 4–9
of the TP53 gene in both cases, showing positivity for p53
in the anaplastic component. In conclusion, our study shows
that alterations of genes implicated in the regulation of the
G1 to the S phase cell cycle checkpoint contribute to the
process of dedifferentiation in peripheral secondary chon-
drosarcoma (CS), although the molecular mechanisms seem
at least in part to differ from those involved in the process of
dedifferentiation of central CS. PDGFR" could represent a
potential target for treatments with receptor tyrosine kinase
inhibitors in peripheral DCS.
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Introduction
Dedifferentiated chondrosarcoma (DCS) is a well-known
entity defined as a well-differentiated cartilage tumor juxta-
posed with abrupt transition to a high-grade non-
cartilaginous sarcoma. The process of dedifferentiation usu-
ally takes place in central chondromas or low-grade second-
ary chondrosarcoma (CS), but in rare instances, a high-grade
non-cartilaginous sarcoma may originate in a low-grade
peripheral CS secondary to a preexisting osteochondroma
[1, 2]. The incidence of peripheral DCS has ranged between
8.9% and 13.7% of all DCS [1, 3], and they approximately
represented 5.5% of all cases of CS arising in preexisting
exostoses [2]. Tumors occurred both in patients with multi-
ple hereditary exostoses (multiple osteochondromas) or in
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preexisting osteochondromas, the most common location be-
ing the pelvis [2]. Dedifferentiation takes place either syn-
chronously, when both components are present side by side in
the same lesion, or metachronously, when a high-grade sarco-
ma is diagnosed at the same site of a previously excised
osteochondroma or secondary peripheral CS [2]. Overall, the
prognosis is poor, although a better cure rate has been
obtained with a combination of surgery and chemotherapy [2].
In the attempt to further characterize the clinicopathologic
features of these rare tumors, here, we describe the features of
four cases of peripheral DCS arising in osteochondroma.
Moreover, we carried out an analysis of the status of a number
of regulators involved in the G1-S checkpoint, including p53,
MDM-2, cyclin D1, p16, and RB oncoproteins, to determine
whether aberrations of these regulatory pathways may be
involved in the process of dedifferentiation in these tumors.
Finally, we studied the expression of PDGF receptors ! and ",
which have recently been identified as possibly implicated in
the growth of CS, in both tumor components.
Materials and methods
Patients
Thirty-six patients diagnosed with DCS in the years 1995–
2010 were identified in the files of the Section of Anatomic
Pathology of the Department of Critical Care Medicine and
Surgery, University of Florence. Of these, four tumors
(11.1%) had developed in a preexisting osteochondroma.
Patient charts, radiographs, histological slides, and paraffin
blocks were retrieved in each case. Patient details are sum-
marized in Table 1.
Immunohistochemistry
A panel of well-characterized antibodies was used, which
included mouse monoclonal antibodies to p53 (clone DO-7,
pre-diluted; Ventana Medical Systems, Inc., Tucson, AZ),
MDM-2 (clone IF2; Histo-Line Laboratories, Milan, Italy),
p16 (clone 16P04, pre-diluted; Cell Marque), RB (clone
1F8, 1:50 dilution; NeoMarkers, Fremont, CA), cyclin D1
(clone SP4, pre-diluted; Ventana Medical Systems, Inc.),
PDGFR! (sc-338, 1:200 dilution; Santa Cruz Biotechnolo-
gy, Santa Cruz, CA), and PDGFRβ (sc-339, 1:100 dilution;
Santa Cruz Biotechnology).
Immunohistochemistry was performed using a Ventana
BenchMark\ XT automated staining system (Ventana Med-
ical Systems). For antigen retrieval, slides were heated with
Cell Conditioning Solution 1 (CC1) for 30 min. Endoge-
nous biotin was blocked with the appropriate kit. Primary
antibodies against p53, p16, and cyclin D1 were then ap-
plied for 32 min at 37°C in a BenchMark\ XT stainer and
revealed with the iVIEW DAB detection kit, yielding a
brown reaction product. After the staining run was com-
plete, the slides were removed from the autostainer, counter-
stained with hematoxylin, dehydrated, and mounted with
permanent mounting medium.
For RB, PDGFR!, and PDGFR" immunohistochemical
analyses, antigen retrieval was routinely performed in ther-
mostat bath, PT Link Dako, at 97°C with EDTA (pH 9.0) for
15 min. The sections were placed in the Dako Autostainer
Link 48 (Dako, Glostrup, Denmark) and the primary anti-
bodies then applied for 60 min at 20°C. Bound antibodies
were visualized using the Envision™ FLEX and DAB with
chromogen.
For negative controls, primary antibodies were substitut-
ed with PBS.
TP53 gene sequencing
Ten serial sections (thickness, 5 μm) were obtained from
one paraffin-embedded tissue block from the lesions of
patients 2 and 4. Tissue fragments were microdissected
using stereomicroscopic visualization from blank deparaffi-
nized slides in order to separate the chondrogenic and
Table 1 Summary of the clinicopathologic features of four cases of dedifferentiated peripheral chondrosarcomas
Patient Age Sex Site Chondrogenic
component
Anaplastic component Treatment Outcome
1 64 F Proximal tibia G2 Osteosarcoma Resection and reconstruction with
modular prosthesis
Lost at follow-up











Anterior pelvic arch resection
without reconstruction. Local
recurrence treated with resection
and modular prosthesis
Local recurrence on femoral
head after 8 months.
Synchronous inguinal lymph
node and L4 metastasis
4 55 M Scapula G1 Undifferentiated
pleomorphic sarcoma
Partial scapular resection Multiple local recurrences and
pulmonary metastases after
4 months
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dedifferentiated areas of the tumor. Post-microdissected
slides were evaluated to confirm accurate sample microdis-
section. DNA was extracted from the microdissected
paraffin-embedded tissues using a manual protocol [4]. Po-
lymerase chain reaction (PCR) primers for exons 4–9,
encoding the DNA-binding domain of the TP53 gene, were
designed to obtain fragments of no more than 300 bp. Am-
plification reactions were performed with 60 ng of DNA,
10 ng of each primer, 200 μM dNTPs, 1× PCR reaction
buffer, and 2.5 U Taq polymerase in a final volume of 25 μl.
PCR products were sequenced directly on both strands using
an ABI PRISM 3130XL Genetic Analyzer (Perkin-Elmer
Applied Biosystems, Foster City, CA, USA).
Results
Clinical features
The clinical features of the patients, including treatment and
follow-up, are summarized in Table 1. The patients were two
men and two women ranging in age between 30 and 64 years.
No patient was affected by multiple hereditary exostoses
(multiple osteochondromas). Three patients reported a mass
present for several years (4, 9, and 30, respectively), with
recent (2–24 months) increase in dimension and onset of pain
in one instance. Two lesions were located in the pelvis, one in
the scapula, and one in the tibia. Radiologically, there was
evidence of a preexisting osteochondroma consisting of a
large lesion arising on the bone surface with irregular periphe-
ric calcifications and ossifications, associated with aggressive
osteolytic areas at the base and periphery of the exostosis,
extending to the bone segment of origin. A soft tissue mass
could be detected by CT scan or MRI (Fig. 1).
Histopathology
Histologically, all tumors had the characteristic biphasic
pattern of dedifferentiated CS and appeared to originate
from a preexisting osteochondroma (synchronous dediffer-
entiation). The cartilaginous component consisted of areas
of well-differentiated grade 1 CS in three lesions and
grade 2 in the remaining one, with diffuse aspects of
calcification and ossification. The dedifferentiated com-
ponent showed features of a high-grade fibroblastic os-
teosarcoma in patient 1 (Fig. 2), while it consisted of a
high-grade undifferentiated pleomorphic sarcoma in the
other three cases (Figs. 3, 4 and 5).
Immunohistochemistry
The results of the immunohistochemical studies are summa-
rized in Table 2 and illustrated in Fig. 6.
Overall, dedifferentiation was consistently accompanied
by the loss of p16 nuclear expression since this protein was
expressed in the chondrogenic component but not in the
anaplastic component in all the cases. In addition, RB pos-
itivity was observed in the anaplastic component in three of
four cases, while this oncoprotein was not detectable in the
chondrogenic areas. Diffuse cyclin D1 nuclear immunore-
activity was present in the high-grade anaplastic component
of all cases, while only one lesion displayed focal positivity
in well-differentiated cartilaginous areas. On the other hand,
there was a limited difference in the expression of p53 in the
two components since it was detected in the anaplastic
component in only two of four cases, while the chondrosar-
comatous areas were negative. Finally, no significant ex-
pression of MDM2 was observed in any of the cases
studied. While PDGFR! was absent in both tumor compo-
nents of dedifferentiated peripheral chondrosarcomas,
PDGFR" was strongly and diffusely positive in all the
cases.
For comparison, we immunostained a series of ten central
conventional chondrosarcomas (six grade 1, three grade 2,
and one grade 3). All these tumors stained diffusely for p16,
RB1, PDGFR!, and PDGFR", while p53 and cyclin D1
were expressed only in one grade 2 and in the grade 3
chondrosarcomas. MDM2 was negative in all cases.
Fig. 1 Sixty-four-year-old woman (patient 1) with history of proximal
tibia osteochondroma. She complained of recent progressive swelling
and pain. a Antero-posterior radiographic view showed a cauliflower-
shaped mass, with ossification and calcifications, arising from the
proximal tibia and scalloping the lateral cortex of the tibia from
outside. b, c The CT scan confirmed the base of implant of the
preexisting osteochondroma on the tibia showing the typical extrofles-
sion of the cortex. Diffuse and irregular osteolysis of the ossifications
within the mass, aggressive erosion of the external surface of the tibial
cortex, and the presence of a soft tissue mass were signs of aggres-
siveness consistent with dedifferentiation
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TP53 gene status
Both cases showing positivity for p53 in the anaplastic
component were analyzed for the status of exons 4–9 of
the TP53 gene. In case 4, we were able to analyze both the
chondrogenic and the anaplastic components, while in case
2 we succeeded in amplifying and screening mutations only
in samples from the anaplastic component. PCR amplifica-
tion and subsequent DNA sequencing revealed no mutations
in the exons examined.
Discussion
The present report confirms that approximately 10% of DCS
occur at the bone surface, developing in a peripheral CS ex-
osteochondroma. The most commonly affected sites are the
pelvis and the long bones of the lower leg (femur and tibia),
reflecting the distribution of secondary peripheral CS [1, 2].
The age at presentation is lower than in central DCS, and the
most common presenting sign is a recent increase in a mass
that had been present for several years. At imaging, the
typical features of a peripheral CS are associated with signs
of local aggressiveness consisting in diffuse and irregular
osteolysis within the mass or at the base of implant and the
presence of tumor extension in the soft tissues.
At variance with central DCS, the high-grade component
of peripheral DCS more often showed a histological appear-
ance of a high-grade spindle cell and pleomorphic sarcoma,
variably classified as fibrosarcoma or malignant fibrous
histiocytoma. However, immunohistochemical analysis
demonstrated the frequent expression of myogenic markers,
including actins and desmin, in the high-grade anaplastic
component [5].
The development of metastatic disease is a frequent event
which is associated with a dismal prognosis. The treatment
of choice is surgery with wide margins, but some benefit in
overall survival has been reported when patients presenting
with localized disease were treated with a combination of
surgery and chemotherapy [2].
The biology of the process of dedifferentiation occurring
in CS has been studied more in depth in central lesions,
while only limited information is available regarding the
molecular characterization of peripheral DCS. Inactivation
of the EXT1 and/or the EXT2 genes is a well-known event
in the development of osteochondromas [6], but it is likely
not involved in the pathogenesis of secondary peripheral CS
[7]. An immunohistochemical analysis of cell signaling
pathways that are known to have an important role in
normal chondrocyte proliferation showed that the FGF sig-
naling pathway is more frequently active than in the chon-
drogenic component of conventional secondary peripheral
CS, whereas PTHLH signaling seems to be low/downregu-
lated [5]. This suggests that these changes may be of im-
portance in the transformation of CS toward DCS.
Moreover, a comparison between the chondrogenic and
anaplastic components showed relevant differences in the
expression of molecules related to cell cycle regulation,
such as cyclin D1 and p53 [5]. Abnormalities in the check-
points controlling cell cycle contribute to tumorigenesis
and progression in several human malignancies; there-
fore, in the present study, we further explored the status
of other players involved in the control of the G1/S
checkpoint. We observed a consistent difference in the
Fig. 2 In patient 1, the high-
grade component of the lesion
showed histological features of
fibroblastic osteosarcoma. a
Low-power view of the lesion
with both low-grade and high-
grade components. b High-
power view of the osteosar-
comatous component
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expression of p16 and cyclin D1, and to a lesser extent
of RB and p53, between the well-differentiated and
anaplastic compartments of peripheral DCS.
According to our results and to previous reports, it
appears that the molecular abnormalities present in periph-
eral DCS differ from those occurring in central DCS.
Figs. 3–5 In the remaining
patients, the tumor consisted of
a low-grade well-differentiated
chondrosarcoma (top) and a
high-grade pleomorphic sarco-
ma (bottom). There is a sharp
separation between the two
components





Pt P53 MDM-2 P16 RB Cyclin D1 PDGF-R α PDGF-R β
CC AC CC AC CC AC CC AC CC AC CC AC CC AC
1 − − − − + − − − − + − − + +
2 − + − − + − − + − − − − + +
3 − − − − + − − + − + − − + +
4 − + − − + − − + − + − − + +
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Indeed, several studies have shown that the process of
dedifferentiation taking place in central CS is consistently
accompanied by an alteration of the p53 pathway. Strong
nuclear immunostaining has been observed in the high-
grade non-cartilaginous component, but not in the low-
grade cartilaginous one [8–10]. In addition, point mutations
of the p53 gene have been identified in the high-grade
component of central DCS, and this has also been associated
with LOH at 17p [8, 10–12]. In one case, a p53 mutation
consisting of a 6-bp deletion starting at the second base of
codon 250 in exon 7 was detected in both the cartilaginous
and the anaplastic components [11].
At partial variance with these findings, in the present
study, we observed that two of the four tumors (50%)
showed immunohistochemical positivity in the anaplastic
component, but molecular analysis did not reveal any alter-
ation of exons 4–9 of the TP53 gene in these cases. A
discordance between the results of immunohistochemical
analysis showing p53 positivity and those of DNA analysis
showing no detectable gene alterations has been repeatedly
reported with variable frequency in bone and soft tissue
sarcomas [13–16]. Several mechanisms are known to be
involved in the stabilization of wild-type p53 protein result-
ing in nuclear accumulation and immunohistochemical
Fig. 6 Representative images
of the immunohistochemical
stains from case 4. Nuclear
positivity for p53 is visible only
in the anaplastic component of
the tumor (bottom), while the
well-differentiated chondrosar-
comatous areas are negative
(top) (a). A higher power detail
of the immunostaining for p53
in the high-grade component is
shown in b. Similarly, RB (e)
and cyclin D1 (f) were present
in the anaplastic component of
the lesion (bottom), while the
well-differentiated component
was negative (top). P16 (d) was
detectable only in the well-
differentiated chondrosarcoma-
tous areas (top) and not in the
high-grade sarcaomatous areas
(bottom). MDM2 (c) and
PDGFR! (g) were negative in
both components, while
PDGFR" was intensely and
diffusely positive (h)
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positivity, including DNA damage in cells and binding to
viral oncogene products or to the MDM2 gene product [17].
This latter mechanism, however, seems to be unlikely in
peripheral DCS since we did not observe any significant
immunoreactivity for MDM2 in our series. Therefore, al-
though the number of cases analyzed is small, the data
obtained indicate that a molecular alteration of the p53 gene
is unlikely to be involved in the growth and dedifferentia-
tion of peripheral CS arising in osteochondromas. However,
we cannot exclude the presence of TP53 mutations outside
exons that were screened in this study.
Other molecular abnormalities previously identified in
central DCS include genetic and epigenetic alterations of
other genes involved in cell cycle control, including the RB
p16INK4, FHIT, and E-cadherin genes [18, 19]. Interesting-
ly, p16INK4 promoter methylation was observed in both the
low-grade and the high-grade compartments of central DCS,
while in our study, p16 expression was maintained in the
well-differentiated component of the tumor. Therefore, in-
activation of cell cycle genes involved in the G1/S arrest
seems to be an early event in the development of central
DCS, while it appears to occur later in the process of
dedifferentiation of peripheral CS.
Recent studies [20, 21] have investigated the status of
platelet-derived growth factor (PDGF) receptors and their
ligands in conventional CS as they could represent possible
Fig. 6 (continued)
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candidates for molecular therapies with receptor tyrosine
kinase (RTK) inhibitors. The immunohistochemical and
biochemical analyses showed that CS co-expressed
PDGFR! and PDGFR", with the latter showing greater
protein expression and phosphorylation levels. Conversely,
no activating mutations were found [21]. These findings are
in keeping with the existence of an autocrine/paracrine loop
which could play an important role in the development of
conventional central CS. To our knowledge, the status of
PDGFRs has not been previously investigated in DCS. In
the present study, all four cases of peripheral DCS were
intensely and diffusely positive for PDGFR" in both com-
ponents, while PDGFR! was not detectable. These findings
may suggest that PDGFR" could represent a potential target
for treatments with RTK inhibitors in peripheral DCS.
In summary, our study shows that alterations of genes
implicated in the regulation of the G1 to the S phase cell
cycle checkpoint contribute to the process of dedifferentia-
tion in peripheral secondary CS, although the molecular
mechanisms seem at least in part to differ from those in-
volved in the process of dedifferentiation of central CS.
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